Novartis AG
NVSEF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $240,675,400 | $233,760,000 | $216,420,960 | $190,950,700 |
| - Cash | $9,556,000 | $6,656,000 | $7,062,044 | $11,459,000 |
| + Debt | $32,022,000 | $32,637,000 | $31,270,000 | $31,258,000 |
| Enterprise Value | $263,141,400 | $259,741,000 | $240,628,916 | $210,749,700 |
| Revenue | $14,358,000 | $14,836,000 | $13,620,000 | $13,558,000 |
| % Growth | -3.2% | 8.9% | 0.5% | – |
| Gross Profit | $10,819,000 | $11,514,000 | $10,393,000 | $10,234,000 |
| % Margin | 75.4% | 77.6% | 76.3% | 75.5% |
| EBITDA | $5,841,000 | $6,076,000 | $5,831,000 | $5,188,000 |
| % Margin | 40.7% | 41% | 42.8% | 38.3% |
| Net Income | $3,928,000 | $4,041,000 | $3,661,918 | $2,818,000 |
| % Margin | 27.4% | 27.2% | 26.9% | 20.8% |
| EPS Diluted | 2 | 2.06 | 1.82 | 1.41 |
| % Growth | -2.9% | 13.2% | 29.1% | – |
| Operating Cash Flow | $6,571,000 | $6,664,000 | $3,645,000 | $4,193,000 |
| Capital Expenditures | -$831,000 | -$558,000 | -$254,000 | -$1,131,000 |
| Free Cash Flow | $5,740,000 | $6,106,000 | $3,391,000 | $3,062,000 |